Rice Hall James & Associates LLC raised its stake in Mednax Inc. (NYSE:MD) by 3.0% during the second quarter, Holdings Channel reports. The institutional investor owned 28,160 shares of the company’s stock after buying an additional 833 shares during the period. Rice Hall James & Associates LLC’s holdings in Mednax were worth $2,040,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. First Quadrant L P CA purchased a new position in shares of Mednax during the second quarter worth approximately $130,000. Middleton & Co Inc MA purchased a new position in shares of Mednax during the second quarter worth approximately $221,000. JFS Wealth Advisors LLC purchased a new position in shares of Mednax during the second quarter worth approximately $232,000. P.R. Herzig & Co. Inc. purchased a new position in shares of Mednax during the second quarter worth approximately $239,000. Finally, Atria Investments LLC purchased a new position in shares of Mednax during the second quarter worth approximately $414,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.
Shares of Mednax Inc. (NYSE:MD) traded down 1.17% during trading on Friday, reaching $66.12. The company’s stock had a trading volume of 692,755 shares. The company has a 50 day moving average of $65.56 and a 200 day moving average of $68.30. The company has a market cap of $6.10 billion, a PE ratio of 18.45 and a beta of 0.54. Mednax Inc. has a 12-month low of $61.40 and a 12-month high of $83.20.
Mednax (NYSE:MD) last issued its quarterly earnings data on Thursday, July 28th. The company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.07 by $0.04. Mednax had a net margin of 11.17% and a return on equity of 14.88%. The business had revenue of $772 million for the quarter, compared to analysts’ expectations of $775.68 million. During the same quarter in the prior year, the company posted $0.90 EPS. The business’s revenue for the quarter was up 14.1% on a year-over-year basis. On average, analysts anticipate that Mednax Inc. will post $4.14 EPS for the current fiscal year.
A number of brokerages have recently commented on MD. Citigroup Inc. dropped their price target on Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 17th. JPMorgan Chase & Co. dropped their price objective on Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 29th. Zacks Investment Research raised Mednax from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a report on Wednesday, June 29th. Mizuho reissued a “buy” rating and set a $79.00 price objective on shares of Mednax in a report on Tuesday, September 20th. Finally, Jefferies Group dropped their price objective on Mednax from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, August 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. Mednax presently has an average rating of “Buy” and a consensus price target of $76.11.
In other news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the completion of the sale, the director now owns 12,755 shares in the company, valued at approximately $829,202.55. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 2.40% of the company’s stock.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax Inc. (NYSE:MD).
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.